Integrated DNA Technologies and Aldevron Launch New mRNA Solutions to Simplify Base and Prime Editing

Danaher (NYSE: DHR) companies Integrated DNA Technologies and Aldevron are jointly launching research-grade mRNA solutions for base and prime gene editing.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Danaher companies IDT and Aldevron bring gene editing expertise and mRNA manufacturing together to help researchers tackle efficiency, targeting, and workflow challenges in base and prime editing
• PE Ultra mRNA, chemically modified Alt-R™ prime editing guide RNAs (pegRNAs) and design support help researchers improve editing efficiency and narrow candidates for testing
• Six stocked ABE8e base editor mRNAs and a parallel screening kit help researchers pinpoint the best-fit editor for each target

CORALVILLE, Iowa & FARGO, N.D.--(BUSINESS WIRE)-- Danaher companies Integrated DNA Technologies (IDT), a global leader in genomics, and Aldevron, a premier manufacturing partner for DNA, RNA, and protein, are jointly launching new research-grade mRNA solutions designed to simplify base and prime editing workflows. The launch brings IDT’s gene editing expertise and Aldevron’s mRNA manufacturing together within Danaher’s connected ecosystem to address researchers’ increasingly specialized editing needs. Building on the companies’ recently launched wild type and SpyFi™ high-fidelity S.p. Cas9 mRNA portfolio, the expanded offering gives researchers more mRNA options for applications requiring precise, programmable changes to genomic DNA without double-strand breaks.

Integrated DNA Technologies (IDT) and Aldevron are jointly launching new research-grade mRNA solutions for base and prime editing. New offerings include PE Ultra mRNA, chemically modified Alt-R pegRNAs, pegRNA design support, six stocked ABE8e base editor mRNAs, and a parallel screening kit. These connected options help researchers design, screen, and optimize precision-editing workflows, reduce complexity, and identify solutions suited to their targets

Meeting the shift to precision editing

As mRNA delivery and next-generation editing approaches advance, developers face increasingly specialized challenges: improving prime editing efficiency, narrowing pegRNA candidates for testing, and identifying base editors suited to their targets. Addressing these challenges takes complementary expertise across multiple workflow steps. Within Danaher’s connected science ecosystem, IDT and Aldevron bring CRISPR engineering, guide RNA design, and analysis expertise together with mRNA manufacturing to develop solutions around those needs. The resulting portfolio connects options for designing, screening, and optimizing base and prime editing workflows, helping researchers reduce complexity and maintain greater continuity as programs progress.

“The challenge is not simply to make more editing tools available—it is to bring the right capabilities together around the problems researchers need to solve,” said Christopher Vakulskas, senior director, applied science and molecular design at Integrated DNA Technologies. “Together with Aldevron, we’re addressing the realities of increasingly precise gene editing workflows by combining PE Ultra mRNA, optimized Alt-R pegRNAs, and enhanced design support that narrows testing to a practical set of candidates. Bringing these solutions together connects scientific expertise with practical workflow needs, helping researchers reduce complexity and move their programs forward with greater confidence.”

Tackling efficiency and targeting hurdles

Base editing enables a single, targeted nucleotide change, while prime editing supports precise substitutions, insertions, and deletions. Both do so without creating a double-strand break in the target DNA, an important consideration for researchers developing therapeutic applications. Prime editing, however, often struggles to reach efficient editing rates across targets and cell types. To address this, IDT and Aldevron developed PE Ultra mRNAs, which feature an engineered prime editor, and Alt‑R™ pegRNAs that contain a proprietary chemical modification pattern designed to enhance editing performance.

For base editing, researchers can face a different challenge such as protospacer‑adjacent motif (PAM) restrictions and variable editor activity, which can limit the number of targetable sites and make it difficult to identify the optimal editor for a given application. For greater flexibility, the companies now offer six stocked ABE8e-based mRNA variants spanning different PAM compatibilities and fidelity profiles, plus a screening kit for evaluating all six editors in parallel.

IDT has also released Alt-R CRISPR-Cas9 sgRNA XT to maximize editing performance across both base editing and Cas9-mediated workflows using mRNA. Together with the new IDT bioinformatics tool for pegRNA design, these solutions give researchers connected options for designing, screening, and optimizing precision-editing workflows.

Building a more connected gene editing portfolio

The launch builds on IDT and Aldevron’s September 2026 introduction of stocked research-grade S.p. Cas9 mRNA in wild type and SpyFi™ high-fidelity formats. That initial offering provided mRNA-based options for gene editing workflows, which are particularly well-suited for in vivo applications, and established a path to scaled CGMP-manufactured versions for streamlined progression of therapeutic programs.

The new stocked base and prime editing mRNA products are orderable at scales of 20 ug to 1 mg, with larger scales available at Aldevron via custom order. For product details and data, visit www.IDTDNA.com/BasePrimeEditing.

Disclaimer: Integrated DNA Technologies (IDT) offers both Research Use Only (RUO) and In Vitro Diagnostic (IVD) products; Aldevron provides Research Grade (RG) and Current Good Manufacturing Practice (CGMP) products. RUO and RG products are intended for research use only and are not for use in diagnostic or therapeutic procedures. IVD and CGMP products are intended for diagnostic or clinical applications as specified in product documentation. References to clinical, diagnostic, or therapeutic impact pertain only to products with appropriate regulatory clearance. Purchasers are responsible for ensuring appropriate use and compliance with applicable regulations. For further information about product classifications and intended uses, please contact our regulatory affairs team or refer to product documentation.

About IDT

Building from a strong foundation of innovation, expertise, and reliability, Integrated DNA Technologies (IDT) has evolved from an oligo manufacturer to a leading genomics provider. We work shoulder-to-shoulder with scientific and global health partners to enable genomics breakthroughs at scale. Our vision of enabling researchers to rapidly move from the lab to life-changing advances reflects our ongoing commitment to a healthier, brighter future for all.

For more information about IDT, visit www.idtdna.com and follow the company on LinkedIn, X, YouTube, Instagram and Bluesky.

About Aldevron

Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, mRNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies and other treatments. As a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. To learn more about how Aldevron is advancing biological science, visit www.aldevron.com/about-us.

About Danaher

Danaher is a leading global life sciences, diagnostics and biotechnology innovator committed to advancing the power of science and technology to improve human health. Through a connected ecosystem of industry-leading businesses, the Company works closely with customers to solve many of their most complex scientific challenges by accelerating discovery, development and delivery of life-changing therapies. Powered by the Danaher Business System and 60,000 associates worldwide, the Company strives for continuous improvement, operational excellence and Innovation at the Speed of Life. Explore more at www.danaher.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104375435/en/

Media Contacts:

Integrated DNA Technologies
Kristina Sarenas
Director, Public Relations
ksarenas@idtdna.com
(714) 213-9468

Aldevron
Ellen Shafer
Senior Director of Communications
ellen.shafer@aldevron.com
(701) 219-0333

Source: Integrated DNA Technologies

Key Terms

pegrnas technical

Engineered RNA molecules used in CRISPR prime editing that combine a guide sequence to direct the editing enzyme to a specific DNA site with a short template that encodes the desired DNA change; they tell a Cas9-derived nicking enzyme fused to a reverse transcriptase where to cut and what new bases to write. They enable precise, small base changes or short insertions/deletions without making a double‑strand break, but their effectiveness and the types of edits they can introduce depend on the pegRNA design, the target sequence, and the prime editor protein used.

protospacer-adjacent motif (pam) technical

A short, specific DNA sequence immediately next to a target site that CRISPR-associated (Cas) proteins require to recognize and cut DNA. Different Cas enzymes need different PAM sequences; the presence of the correct PAM lets the Cas protein bind and cleave the adjacent target sequence, and the requirement for a PAM also helps the CRISPR system distinguish foreign DNA from the organism’s own CRISPR storage sequences which lack the PAM.

double-strand break medical

A double-strand break is a type of DNA damage where both complementary strands of the DNA helix are severed at the same location. Cells repair these breaks using distinct pathways—principally non-homologous end joining (which directly rejoins ends and can introduce small errors) and homology-directed repair (which uses a matching DNA template and is generally more accurate)—and unrepaired or misrepaired double-strand breaks can lead to mutations, chromosomal rearrangements, or cell death.

cgmp regulatory

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.